2023
Prognostic Factors of COVID‐19: An Umbrella Review Endorsed by the International Society for Pharmacoepidemiology
Sarri G, Liu W, Zabotka L, Freitag A, Claire R, Wangge G, Elvidge J, Dawoud D, Bennett D, Wen X, Li X, Rentsch C, Uddin J, Ali M, Gokhale M, Déruaz‐Luyet A, Moga D, Guo J, Zullo A, Patorno E, Lin K. Prognostic Factors of COVID‐19: An Umbrella Review Endorsed by the International Society for Pharmacoepidemiology. Clinical Pharmacology & Therapeutics 2023, 114: 604-613. PMID: 37342987, DOI: 10.1002/cpt.2977.Peer-Reviewed Original ResearchConceptsPrognostic factorsUmbrella reviewHigh riskIntensive care unit admissionShort-term adverse outcomesCOVID-19AMSTAR-2 toolSystematic literature reviewCare unit admissionRisk of hospitalizationKey prognostic factorsHigh-risk groupCoronavirus disease 2019 (COVID-19) pandemicCOVID-19 outcomesDisease 2019 pandemicComparative effectiveness researchInternational SocietyCOVID-19 disparitiesUnit admissionLong COVIDMale sexAdverse outcomesOptimal careFemale sexHeart diseaseTrends, variation, and clinical characteristics of recipients of antiviral drugs and neutralising monoclonal antibodies for covid-19 in community settings: retrospective, descriptive cohort study of 23.4 million people in OpenSAFELY
Green A, Curtis H, Higgins R, Nab L, Mahalingasivam V, Smith R, Mehrkar A, Inglesby P, Drysdale H, DeVito N, Croker R, Rentsch C, Bhaskaran K, Tazare J, Zheng B, Andrews C, Bacon S, Davy S, Dillingham I, Evans D, Fisher L, Hickman G, Hopcroft L, Hulme W, Massey J, MacDonald O, Morley J, Morton C, Park R, Walker A, Ward T, Wiedemann M, Bates C, Cockburn J, Parry J, Hester F, Harper S, Douglas I, Evans S, Goldacre B, Tomlinson L, MacKenna B. Trends, variation, and clinical characteristics of recipients of antiviral drugs and neutralising monoclonal antibodies for covid-19 in community settings: retrospective, descriptive cohort study of 23.4 million people in OpenSAFELY. BMJ Medicine 2023, 2: e000276. PMID: 36936265, PMCID: PMC9951378, DOI: 10.1136/bmjmed-2022-000276.Peer-Reviewed Original ResearchDescriptive cohort studyHigh-risk groupSevere outcomesHigh riskCohort studyHome residentsRisk groupsAntiviral drugsCOVID-19Community settingsMonoclonal antibodiesCasirivimab/imdevimabLow treatment coverageNHS regionProportion of patientsCOVID-19 infectionRoutine clinical dataOpenSAFELY platformUnvaccinated patientsClinical characteristicsLiver diseaseClinical dataTreatment coverageEligibility criteriaPatients
2022
Rates of serious clinical outcomes in survivors of hospitalisation with COVID-19 in England: a descriptive cohort study within the OpenSAFELY platform
Collaborative T, Tazare J, Walker A, Tomlinson L, Hickman G, Rentsch C, Williamson E, Bhaskaran K, Evans D, Wing K, Mathur R, Wong A, Schultze A, Bacon S, Bates C, Morton C, Curtis H, Nightingale E, McDonald H, Mehrkar A, Inglesby P, Davy S, MacKenna B, Cockburn J, Hulme W, Warren-Gash C, Bhate K, Nitsch D, Powell E, Mulick A, Forbes H, Minassian C, Croker R, Parry J, Hester F, Harper S, Eggo R, Evans S, Smeeth L, Douglas I, Goldacre B. Rates of serious clinical outcomes in survivors of hospitalisation with COVID-19 in England: a descriptive cohort study within the OpenSAFELY platform. Wellcome Open Research 2022, 7: 142. PMID: 37362009, PMCID: PMC10285340, DOI: 10.12688/wellcomeopenres.17735.1.Peer-Reviewed Original ResearchDeep vein thrombosisCOVID-19 patientsHigh riskGeneral populationOpenSAFELY platformPulmonary embolismMyocardial infarctionCOVID-19Type 2 diabetes mellitus diagnosisSerious clinical outcomesPrimary care recordsDescriptive cohort studyCOVID-19 populationRisk of outcomesDiabetes mellitus diagnosisAge/sexMajority of outcomesPulmonary complicationsComparator cohortCohort studyIschemic strokeVein thrombosisHeart failureClinical outcomesAdverse outcomesOverall and cause-specific hospitalisation and death after COVID-19 hospitalisation in England: A cohort study using linked primary care, secondary care, and death registration data in the OpenSAFELY platform
Bhaskaran K, Rentsch CT, Hickman G, Hulme WJ, Schultze A, Curtis HJ, Wing K, Warren-Gash C, Tomlinson L, Bates CJ, Mathur R, MacKenna B, Mahalingasivam V, Wong A, Walker AJ, Morton CE, Grint D, Mehrkar A, Eggo RM, Inglesby P, Douglas IJ, McDonald HI, Cockburn J, Williamson EJ, Evans D, Parry J, Hester F, Harper S, Evans SJ, Bacon S, Smeeth L, Goldacre B. Overall and cause-specific hospitalisation and death after COVID-19 hospitalisation in England: A cohort study using linked primary care, secondary care, and death registration data in the OpenSAFELY platform. PLOS Medicine 2022, 19: e1003871. PMID: 35077449, PMCID: PMC8789178, DOI: 10.1371/journal.pmed.1003871.Peer-Reviewed Original ResearchConceptsCOVID-19 patientsCOVID-19 hospitalisationGeneral population controlsCOVID-19 groupCOVID-19 survivorsHospital admissionHigh riskInfluenza hospitalisationsCause mortalityCohort studyInfluenza patientsPrimary careGeneral populationInitial infectionAcute coronavirus disease 2019Lower respiratory tract infectionsSevere COVID-19 outcomesLong-term adverse outcomesCOVID-19 hospital admissionsSpecific causesPopulation controlsCause-specific hospitalisationRespiratory tract infectionsCause-specific outcomesPotential risk factors
2021
Protease inhibitor-based direct-acting antivirals are associated with increased risk of aminotransferase elevations but not hepatic dysfunction or decompensation
Torgersen J, Newcomb CW, Carbonari DM, Rentsch CT, Park LS, Mezochow A, Mehta RL, Buchwalder L, Tate JP, Bräu N, Bhattacharya D, Lim JK, Taddei TH, Justice AC, Lo Re V. Protease inhibitor-based direct-acting antivirals are associated with increased risk of aminotransferase elevations but not hepatic dysfunction or decompensation. Journal Of Hepatology 2021, 75: 1312-1322. PMID: 34333102, PMCID: PMC8604762, DOI: 10.1016/j.jhep.2021.07.021.Peer-Reviewed Original ResearchConceptsSevere hepatic dysfunctionBaseline FIB-4Acute liver injuryHepatic dysfunctionInhibitor-based treatmentHepatic decompensationFIB-4Liver injuryHigh riskDAA therapyHazard ratioAdvanced liver fibrosis/cirrhosisRisk of ALIProtease inhibitor-based regimensProtease inhibitor-based treatmentLiver fibrosis/cirrhosisInhibitor-based regimensHepatitis C infectionSevere liver dysfunctionFibrosis/cirrhosisInhibitor-based therapyAminotransferase elevationChronic HCVALT elevationC infectionUK prevalence of underlying conditions which increase the risk of severe COVID-19 disease: a point prevalence study using electronic health records
Walker JL, Grint DJ, Strongman H, Eggo RM, Peppa M, Minassian C, Mansfield KE, Rentsch CT, Douglas IJ, Mathur R, Wong AYS, Quint JK, Andrews N, Bernal JL, Scott JA, Ramsay M, Smeeth L, McDonald HI. UK prevalence of underlying conditions which increase the risk of severe COVID-19 disease: a point prevalence study using electronic health records. BMC Public Health 2021, 21: 484. PMID: 33706738, PMCID: PMC7948667, DOI: 10.1186/s12889-021-10427-2.Peer-Reviewed Original ResearchConceptsSevere COVID-19Health conditionsElectronic health recordsHigh riskRisk populationsCOVID-19Clinical Practice Research Datalink GOLDSevere COVID-19 diseaseSecondary care recordsChronic kidney diseaseHealth recordsChronic liver diseasePoint prevalence studyBinomial exact confidence intervalsOlder age groupsPublic health interventionsWorking-aged individualsCOVID-19 diseaseWorking-aged adultsUK prevalenceCurrent asthmaLiver diseaseCancer survivorsPoint prevalenceKidney disease
2020
Safety of Gabapentin Prescribed for Any Indication in a Large Clinical Cohort of 571,718 US Veterans with and without Alcohol Use Disorder
Rentsch CT, Morford KL, Fiellin DA, Bryant KJ, Justice AC, Tate JP. Safety of Gabapentin Prescribed for Any Indication in a Large Clinical Cohort of 571,718 US Veterans with and without Alcohol Use Disorder. Alcohol Clinical And Experimental Research 2020, 44: 1807-1815. PMID: 32628784, PMCID: PMC7540277, DOI: 10.1111/acer.14408.Peer-Reviewed Original ResearchConceptsAlcohol use disorderMental statusRelative riskGabapentin exposureUse disordersICD-9 diagnostic codesAdverse neurologic effectsPotential medication interactionsAltered mental statusIncidence of fallsClear dose-response relationshipLarge clinical cohortDose-response relationshipRace/ethnicityUnexposed patientsHepatitis CAdverse eventsMedication interactionsExcess riskNeurologic effectsUS veteransDiagnostic codesIncidence rateClinical cohortHigh riskFactors associated with COVID-19-related death using OpenSAFELY
Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, Curtis HJ, Mehrkar A, Evans D, Inglesby P, Cockburn J, McDonald HI, MacKenna B, Tomlinson L, Douglas IJ, Rentsch CT, Mathur R, Wong AYS, Grieve R, Harrison D, Forbes H, Schultze A, Croker R, Parry J, Hester F, Harper S, Perera R, Evans SJW, Smeeth L, Goldacre B. Factors associated with COVID-19-related death using OpenSAFELY. Nature 2020, 584: 430-436. PMID: 32640463, PMCID: PMC7611074, DOI: 10.1038/s41586-020-2521-4.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAge DistributionAge FactorsAgedAged, 80 and overAgingAsian PeopleAsthmaBetacoronavirusBlack PeopleCohort StudiesCoronavirus InfectionsCOVID-19Diabetes MellitusFemaleHumansHypertensionMaleMiddle AgedPandemicsPneumonia, ViralProportional Hazards ModelsRisk AssessmentSARS-CoV-2Sex CharacteristicsSmokingState MedicineYoung AdultConceptsCOVID-19-related deathsPrimary care electronic health recordsPrimary care recordsLarge cohort studyCoronavirus disease 2019Electronic health recordsSevere asthmaCohort studyClinical factorsSouth Asian peopleSevere outcomesDisease 2019Medical conditionsHigh riskOpenSAFELYWhite ethnicityCare recordsNHS EnglandPatient recordsPatient dataHealth recordsDeathGreater ageAsian peopleRisk
2015
Alcohol-Related Diagnoses and All-Cause Hospitalization Among HIV-Infected and Uninfected Patients: A Longitudinal Analysis of United States Veterans from 1997 to 2011
Rentsch C, Tate JP, Akgün KM, Crystal S, Wang KH, Ryan Greysen S, Wang EA, Bryant KJ, Fiellin DA, Justice AC, Rimland D. Alcohol-Related Diagnoses and All-Cause Hospitalization Among HIV-Infected and Uninfected Patients: A Longitudinal Analysis of United States Veterans from 1997 to 2011. AIDS And Behavior 2015, 20: 555-564. PMID: 25711299, PMCID: PMC4550577, DOI: 10.1007/s10461-015-1025-y.Peer-Reviewed Original ResearchConceptsAlcohol-related diagnosesHospitalization ratesUnited States veteransUninfected patientsCause hospitalizationHIV infectionStates veteransUninfected individualsMultivariable Cox proportional hazards modelsCox proportional hazards modelOverall hospitalization rateProportional hazards modelCancer admissionsAntiretroviral therapyMultivariable adjustmentHIV serostatusComorbidity variablesHospitalization trendsRelative riskHigh riskHazards modelHIVHospitalizationDisease categoriesPatients